Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis : Episode 11
Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis
Medical experts discuss the failure of evobrutinib to meet its primary endpoint in phase 3 trials, review the primary outcomes of the phase 2B study of tolebrutinib in relapsing multiple sclerosis, examine payers' perspectives on the currently available data for tolebrutinib, and briefly describe the design of the HERCULES trial.
EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis
EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression
EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis
EP: 4.Examining Key Unmet Needs in Multiple Sclerosis
EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies
EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making
EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment
EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies
EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
Now Viewing
EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis
EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies
EP: 13.Multiple Sclerosis: Looking Toward the Future
Video content above is prompted by the following questions:
- Evobrutinib did not meet its primary endpoint in phase 3 trials. Were you surprised by these results?
- What were the primary outcomes of the phase 2B study of tolebrutinib in relapsing multiple sclerosis?
- What was seen in the 3-year data?
- How do payers view the currently available data of tolebrutinib?
- Tolebrutinib is also under investigation in non-relapsing secondary progressive multiple sclerosis. Why is there a need to investigate therapies in this phenotype and what is the phase 3 HERCULES trial design?
Related Videos
Related Content
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials
January 9th 2025Article
Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).
Read More
